The diversity and complexity of the human brain are widely assumed to be encoded within a constant genome. Somatic gene recombination, which changes germline DNA sequences to increase molecular diversity, could theoretically alter this code but has not been documented in the brain, to our knowledge. Here we describe recombination of the Alzheimer's disease-related gene APP, which encodes amyloid precursor protein, in human neurons, occurring mosaically as thousands of variant 'genomic cDNAs' (gencDNAs). gencDNAs lacked introns and ranged from full-length cDNA copies of expressed, brain-specific RNA splice variants to myriad smaller forms that contained intra-exonic junctions, insertions, deletions, and/or single nucleotide variations. DNA in situ hybridization identified gencDNAs within single neurons that were distinct from wild-type loci and absent from non-neuronal cells. Mechanistic studies supported neuronal 'retroinsertion' of RNA to produce gencDNAs; this process involved transcription, DNA breaks, reverse transcriptase activity, and age. Neurons from individuals with sporadic Alzheimer's disease showed increased gencDNA diversity, including eleven mutations known to be associated with familial Alzheimer's disease that were absent from healthy neurons. Neuronal gene recombination may allow 'recording' of neural activity for selective 'playback' of preferred gene variants whose expression bypasses splicing; this has implications for cellular diversity, learning and memory, plasticity, and diseases of the human brain.
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, analogous to the mechanism of antibody diversification that was later identified 2 , but this has not been described in the brain 3, 4 . Nevertheless, later identification of genomic mosaicism 5 , which arises somatically to produce brain cells with distinct if seemingly random genomic changes, suggested genome dynamism that might include gene recombination. Genomic mosaicism was first identified in neural progenitor cells and neurons as aneuploidies and DNA content variation, both representing large copy number variations (CNVs) [6] [7] [8] . Randomly distributed, smaller megabase-scale CNVs, LINE1 repeat elements, and single nucleotide variations (SNVs) were subsequently identified. Genomic mosaicism can influence cell survival and gene transcription, but somatic gene recombination of specific genes has not been reported 5, 9 . A candidate gene for neuronal recombination is APP, which shows mosaic CNVs in normal human brains. These CNVs are increased in sporadic Alzheimer's disease (SAD) 10 , the most common form of Alzheimer's disease. APP is central to the amyloid hypothesis wherein APP is cleaved by secretases to form toxic amyloid-β (Aβ) peptides and plaques, causing Alzheimer's disease 11 . Constitutive APP mutations and duplications are believed to cause rare forms of familial Alzheimer's disease (FAD) and Alzheimer's disease neuropathology in Down syndrome (trisomy 21 with 3 APP copies), supporting the idea that they have a pathogenic role when present mosaically in SAD [12] [13] [14] . We previously identified mosaic, neuronal APP CNVs that showed heterogeneous signals that might be explained by gene recombination 10 . However, interrogation of APP genomic loci (about 0.3 Mb) using low-depth, short-read single-cell sequencing capable of detecting CNVs produced negative results that were complicated by resolution limitations 5, 15 . We therefore developed an alternative strategy focused on APP in small cell populations, using nine distinct methodologies (Extended Data Table 1 ).
Novel APP RNA variants in neurons
We postulated that genomic sequence alterations in APP, existing mosaically, could be detected in RNA through transcriptional amplification. Assessments were focused on small populations of nuclei rather than bulk samples that are dominated by annotated species (Extended Data Fig. 1a ) to detect mosaic alterations. The workflow (Fig. 1a) commenced with fluorescence-activated nuclear sorting (FANS) 16 to isolate neuronal nuclei from prefrontal cerebral cortices from both control individuals and those with verified SAD, which were run in parallel (Extended Data Table 2 ). Groups of 50 NeuN-positive neuronal nuclei were isolated and processed for PCR with reverse transcription (RT-PCR; Fig. 1a ) and downstream analysis. RT-PCR using validated primers on exon 1 and exon 18 (Supplementary Table 1) , which can amplify full-length APP cDNA (APP-770, NM_000484.3), detected the expected splice variants APP-751 (NM_201413.2) and APP-695 (NM_201414.2) 17 (Extended Data Fig. 1b) . However, multiple unexpected bands of varied sizes were also identified (Fig. 1b) . The RT-PCR products were Southern blotted with 32 P-labelled APP cDNA probes (Fig. 1c) , and positive bands were cloned and Sanger sequenced. The new bands yielded APP cDNA sequence variants unlike any previously reported, characterized by loss of central exons with proximal and distal exons linked by intra-exonic junctions (IEJs) (Fig. 1d,e) . Twelve novel RNA variant sequences with unique IEJs were identified in neurons ( Fig. 1e ) and non-neurons displayed no variants (Extended Data  Fig. 1c ). IEJs were independently observed in five oligo-dT-primed cDNA libraries; three from sorted neuronal nuclei from individuals with SAD (Extended Data Fig. 1d ) and two from commercially Article reSeArcH produced long-read RNA-seq data sets from whole brain and temporal lobe of patients with SAD (Extended Data Fig. 1e ). Five variants retained coding potential and seven contained premature stop codons (Extended Data Table 3, Supplementary Table 2 ). One prevalent form was characterized by an IEJ between the 24th nucleotide of exon 3 and the 45th nucleotide of exon 16 (Fig. 1e , R3/16). Detection of R3/16 by RNA in situ hybridization (RISH) on SAD brain sections indicated the cytoplasmic presence of variants (Extended Data Fig. 1f) . Notably, sequence complementarity of joined exons was found in all 12 IEJs, ranging in overlap from 2 to 20 nucleotides (Fig. 1e , Extended Data Table 3, Supplementary Table 2) . Amplification for a second gene related to Alzheimer's disease, PSEN1, did not identify variants (Extended Data Fig. 1g ).
gencDNA sequences in neuronal genomes
The existence of previously unidentified RNA variants raised the question of whether this transcriptional heterogeneity originated from mosaic variation in DNA. We carried out high-stringency amplification, using the APP primers previously used for RNA and cDNA analyses, on RNase-treated DNA extracted from sets of 20 neuronal nuclei from both healthy brains and those with SAD (Fig. 2a) . PCR of the wild-type APP genomic locus was not possible because of its length (about 300 kb) (Fig. 1d) . However, PCR on genomic DNA generated similar-sized bands to novel RNA variants (Fig. 2b, Extended Data  Fig. 2a ). Sanger sequencing revealed multiple gencDNAs and seven of eight were identical to those identified in RNA (Fig. 2c) . We validated the presence of APP gencDNAs in neurons using multiple, distinct primer sets (Extended Data Fig. 2b, c) . We did not detect gencDNAs in DNA isolated from human lung fibroblasts (IMR-90), human embryonic kidney cells (HEK-293), or non-neuronal nuclei from the brains of individuals with or without SAD (Extended Data Fig. 2d, e) . Amplification of PSEN1 did not produce products from genomic DNA (Fig. 2b, Extended Data Fig. 2a) .
gencDNA detection by non-PCR methods
To validate the presence of APP gencDNA junctions within single neuronal genomes without polymerase-based amplification, we developed DNA in situ hybridization (DISH). Our method extensively modified the sample preparation and hybridization protocols (see Methods) of a commercial RISH product, BaseScope (ACD), to recognize genomic sequences. BaseScope technology uses paired ISH probes to eliminate hybridization artefacts and can detect specific junctions. Two DISH probes were extensively used (Extended Data Table 4 ): one that recognized a common gencDNA sequence via the exon 16-exon 17 junction (DISH 16/17 ), which spans the Aβ coding region of APP; and one that recognized the newly identified IEJ formed between exons 3 and 16 (DISH 3/16 ). Bound probes were visualized as red dots with varying diameters. All probes passed multiple specificity requirements involving positive and negative controls. Sense and antisense DISH probes produced similar results in RNase-treated neuronal nuclei from individuals with SAD ( Fig. 2d-i) . By comparison, RNA signals were detected only using the antisense probes (Extended Data Fig. 1f) ; therefore, sense probes were used in all subsequent DISH analyses. Critically, DISH signals were eliminated by destruction of the target sequence by specific (but not off-target) restriction enzyme digestion ( Fig. 2j-m, Extended Data Fig. 2f ). In addition, no DISH signal was detected on cells infected with retroviruses containing wild-type human genomic APP sequences lacking target sequences (Extended Data Fig. 2g, h) . Notably, double labelling with dual DISH probes recognizing the intron 2-exon 3 wild-type genomic sequence combined with DISH 3/16 or DISH 16/17 demonstrated that APP gencDNAs did not usually co-localize with the wild-type locus (Fig. 2n) . Thus, DISH detected specific APP gencDNA junctions within genomic DNA without polymerase-dependent amplification, revealing multiple loci distinct from germline APP alleles.
A completely independent approach also identified APP gencDNAs without primary PCR amplification by using a custom Agilent Neuronal nuclei isolation by FANS 3c S e n s e A n t i s e n s e S e n s e A n t i s e n s e **** 
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SureSelect targeted DNA pull-down (Extended Data Fig. 2i ), which showed unbiased genomic coverage across the entire APP genomic locus (all introns and exons including exon 8; Extended Data Fig. 2j ). Analysis of DNA from 40,000 neuronal nuclei from individuals with SAD identified all previously detected gencDNA exon-exon junctions excluding exon 8, which is absent from the brain-specific APP mRNA splice variants APP-751 and APP-695 ( 
Distinct APP gencDNAs in SAD
The diversity of gencDNA sequences was assessed by a distinct technical approach, single molecule real-time (SMRT) circular consensus sequencing (CCS), which enables high-certainty, long-read calls to be produced by multiple passes over the same template. gencDNAs were enriched by multiple PCR reactions on small neuronal populations from five individuals with SAD (149 reactions from 96,424 nuclei) and five healthy brains (244 reactions from 162,248 nuclei; Fig. 3a ). Samples were pooled for library preparation and SMRT-CCS. Of note, more non-diseased nuclei than diseased nuclei were required to produce sufficient product for sequencing. We identified 6,299 unique sequences (10% in frame; Extended Data Fig. 3a , b) including 45 different IEJs, in neuronal nuclei from the brains of individuals with SAD, and 1,084 unique sequences (12.1% in frame; Extended Data Fig. 3a, c) , including 20 IEJs, in neuronal nuclei from non-diseased brains ( Fig. 3b-i) .
Critically, both qualitative and quantitative differences in the sequences of gencDNA variants distinguished the brains of individuals with SAD from healthy brains ( Fig. 3b-i) . Distinctions included gencDNAs with novel IEJs and SNVs (Fig. 3d , e), which were far more prevalent in the brains of individuals with SAD. By contrast, gencDNAs of the canonical neuronal splice variants, APP-751 and APP-695, predominated in non-diseased brains, and brains from individuals with SAD showed reduced APP-751 and no APP-695 (Fig. 3f, h) . Notably, 11 SNVs that had been previously published as pathogenic FAD mutations (Fig. 3d 34.6% Article reSeArcH activity. Initial results did not show gencDNAs, but induction of DNA strand breaks by H 2 O 2 produced novel gencDNAs (Fig. 4b, c) . Additionally, endogenous reverse transcriptase activity was also required to produce gencDNAs, based on results using the nucleoside reverse transcriptase inhibitors (RTi) abacavir (ABC) and azidothymidine (AZT) (Fig. 4b) . Variant RNAs were also dependent on reverse transcriptase activity (Extended Data Fig. 4 ). Endogenous reverse transcriptase activity was confirmed in CHO cells and further identified in human prefrontal cortex ( Fig. 4d-h ), consistent with gencDNA production from RNA intermediates and reverse transcription (Fig. 4i ).
Increased gencDNAs in SAD and J20 neurons
We further explored the relationships between gencDNAs and SAD using DISH. We examined two gencDNA junctions, DISH 16/17 and DISH 3/16 , in neurons from six individuals with verified SAD and six non-diseased brains (Fig. 5a -f, Extended Data Fig. 5a -f, Extended Data Table 2 ; average age 83.5 and 86.7 years, respectively). The number of red foci in neurons from individuals with SAD was three-to fivefold higher than in non-diseased neurons and ranged from 0 to a maximum of 13 in SAD nuclei. Rare foci were observed in non-neuronal nuclei but were not statistically increased in SAD (Fig. 5a-f , Extended Data Fig. 5a-f ). Increased gencDNAs in neurons from individuals with SAD raised the question of whether gencDNAs could give rise to toxic proteins. We therefore tested the cytotoxicity of three APP RNA variants (R2/18, R3/14, and R3/16), which were translated in vitro, and found that two of the three variants induced cell death in SH-SY5Y cells (Extended Data Fig. 5g, h) . The J20 mouse model of Alzheimer's disease forms Aβ plaques that accumulate with age. These mice harbour multiple copies of a human APP transgene containing the Swedish (K670M/N671L) and Indiana (V717F) mutations, driven by a neuron-specific platelet-derived growth factor-β (PDGF-β) promoter to produce selective, high expression in neurons, with little or no expression in non-neuronal cells 18 . DISH probes for human APP did not detect the endogenous mouse locus (Fig. 5g, Extended Data Fig. 6b) . DISH 3/16 identified enriched signals in J20 neuronal nuclei, contrasting with low levels in non-neuronal nuclei from the same mice (Fig. 5g, h, Extended Data Fig. 6a ). The more prevalent gencDNA sequence recognized by DISH 16/17 was also highly enriched in neurons. Notably, DISH 16/17 demonstrated an age-dependent increase in the area of gencDNA foci over a 2.3-year period, a pattern of change that was not observed in non-neuronal nuclei (Fig. 5i, j,  Extended Data Fig. 6c) . Use of cells infected with retroviral proviruses containing 0, 1, or 2 copies of the DISH 16/17 target sequence demonstrated that DISH is semiquantitative and reflects DNA copy numbers (Extended Data Fig. 6d-f ). The neuron-selective increase in area of foci occurs during adult life, long after cerebral cortical neurogenesis has ceased 19 , further supporting the theory that neuronal gene transcription generates gencDNAs.
Discussion
Human neuronal APP gene recombination was identified in brains from healthy controls and individuals with SAD. It was characterized by the mosaic presence of thousands of distinct gencDNA variants that enter neuronal genomic DNA through a process involving APP transcription that is influenced by neural activity, DNA strand breaks and reverse transcription (Supplementary Discussion). APP gencDNAs bear some resemblance to, but are fundamentally distinct from, processed pseudogenes 20 (non-coding, germline remnants of evolutionarily retrotransposed mRNAs 21, 22 that can be active in cancers 23 ) and LINE1 repeat elements (which encode an active reverse transcriptase (ORF2) 20 to allow potential retrotransposition in mitotic cells, including within the developing brain 5, 9, [24] [25] [26] ). By comparison, APP gencDNAs manifest as thousands of distinct genomic variants derived from a cellular gene, contain IEJs and myriad SNVs, can undergo multiple 'retro-insertions' into post-mitotic neuronal genomes, and appear capable of being actively transcribed and translated to produce variant bioactive products that are relevant to both normal and diseased states.
Constitutive mutations or APP CNVs are considered causal in FAD and Down syndrome, raising the possibility that previously reported somatic APP exonic CNVs contribute mechanistically to SAD 10 , which can be explained by the somatic gene recombination identified here. Proof-of-concept data from individuals with SAD identified a marked shift in the forms and abundance of gencDNAs when compared with healthy controls (Figs. 3, 5) , including the three-to fivefold increase in gencDNAs in all brains from individuals with SAD examined (Fig. 5) . Notably, we identified 11 somatic SNVs that were previously identified as being pathogenic in FAD 12 , which were absent from non-diseased controls. Other SNVs, as well as myriad genomic alterations, may also contribute to SAD through both classical and non-classical mechanisms.
Classical mechanisms that support the amyloid hypothesis involve production of toxic Aβ peptides and plaque formation. gencDNAs, including those with FAD-associated mutations, are likely to represent a source of secretase-cleaved substrate for the production of Aβ, as well as a potential source of toxic products that do not require secretase cleavage (Extended Data Fig. 5 ). Non-ATG translation could potentially occur for out-of-frame variants 27 . Non-classical mechanisms might involve RNA pathologies 28 or maximum limits to gencDNA integration per neuron, beyond which neurodegeneration occurs via genome instability, akin to deleterious mobile elements 29 . The potential diversity of Article reSeArcH protein variants produced by gencDNAs, and other non-protein mechanisms, may help to explain the failure of therapeutic trials targeting Aβ and related enzymologies, especially those targeting single molecular entities 30 . The largest risk factor for SAD is age, and the age-related increase in gencDNA variants in neurons offers a possible explanation for the decades of life required for SAD to manifest. Neuronal APP transcription promotes gencDNA generation both in cell culture and in J20 neurons in vivo (Figs. 4, 5) . This is consistent with the increase in APP transcription that was previously linked to SAD incidence 31 , and the gene encoding the SAD risk factor ApoE4 32 . Notably, the dependence of gencDNA on reverse transcriptase activity might be relevant to the statistical rarity of proven cases of Alzheimer's disease in individuals with HIV infection who are more than 65 years old 33, 34 , and who have received prolonged, combined anti-retroviral therapy (cART), which includes reverse transcriptase inhibitors. If confirmed, this observation would suggest the immediate use of FDA-approved cARTs or modified combinations containing reverse transcriptase inhibitors to treat SAD, Down syndrome and perhaps FAD. Additionally, processes that produce DNA breaks, such as head injury, that have been linked to Alzheimer's disease [35] [36] [37] are consistent with gencDNA production requiring DNA breaks. Thus, gencDNAs and their production have properties relevant to a range of Alzheimer's disease mechanisms and the development of new therapeutic strategies.
The presence of APP gencDNAs in non-diseased neurons is likely to reflect the normal roles of APP 38 , including synaptic function; here, APP gencDNAs might provide an increased repertoire of protein species, contributing to synaptic diversity. Additional genes may be transcriptionally modified and genomically retro-inserted in response to selective activities in neuronal populations. Such a mechanism might enable preferential gene re-expression that bypasses splicing or further RNA modification. More broadly, gencDNAs could provide neurons with an activity-dependent mechanism for recording and retaining information over long periods of time, perhaps placing multiple forms of a gene under transcriptional control distinct from a wild-type locus, which could be produced through diverse genomic integration sites that remain to be determined. Such a process could have relevance to known neuronal functions that depend on transcriptional activity, including Hebbian plasticity 39 , synaptic wiring 40 , learning and memory 41 , and cognition 42 . Thus, gencDNA production may represent both a 'recording' and a 'playback' mechanism for expressing a symphony of variants beyond wild-type gene forms. It would be surprising if APP were the only gene to undergo this form of recombination, which might influence distinct, normal brain functions as well as contributing to brain disorders such as Alzheimer's disease.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0718-6. J20 transgenic mice (B6/Cg-Tg(PDGFB-APPSwInd)20Lms/2JMmjax) were purchased from The Jackson Laboratory and housed in IACUC approved animal facilities in accordance with applicable laws and regulations at Sanford Burnham Prebys Medical Discovery Institute. Sex (F/M) and age (days) of mice used for experiments are listed: F177, M566, M661, M661, M728, F748, F829, and M861. Sample sizes were estimated based upon preliminary data without additional statistics. Samples were allocated randomly and in situ hybridization quantification was blinded for statistical assessments. Nucleus extraction and FANS. Human and mouse brain nuclei were isolated as described previously 10 . For in situ hybridization analyses, isolated nuclei were fixed in 1:10 diluted buffered formalin (Fisher Healthcare) for 5 min. Prior to sorting, fixed or unfixed nuclei were then labelled with anti-NeuN rabbit monoclonal antibody (1:800) (Millipore, Germany) and Alexa Fluor 488 donkey anti-rabbit IgG (1:500) (Life Technologies, Carlsbad, CA), and counterstained with propidium iodide (PI; 50 μg/ml) (Sigma, St. Louis, MO). For DNA analyses, RNase A (100 μg/ml) was included with all subsequent steps after initial nuclei isolation, including primary and secondary antibody incubations. Diploid NeuN-positive and negative nuclei were gated by PI and immunofluorescence, and sorted into appropriate populations for RT-PCR, genomic DNA PCR, or in situ hybridization. Table 1 ) according to the manufacturer's protocol. Oligo-(dT) 20 primer was used to prime the cDNA library as indicated. Low annealing stringency PCR was carried out with the following thermal cycling steps for 40 cycles: 95 °C 15 s, 55 °C for APP and 52 °C for PSEN1 15 s, and 68 °C 2.5 min for APP and 2 min for PSEN1. Southern blotting. RT-PCR products were run on agarose gel, denatured, and transferred to a positively charged nylon membrane. UV-crosslinked membranes were incubated with denatured and purified 32 P-labelled APP cDNA probes at 42 °C overnight. Blots were washed four times with increasing washing stringency and temperature according to established protocols. Images were developed on a Typhoon (GE Healthcare Life Sciences) or Fujifilm FLA-5100 phosphorimager. DNA extraction and genomic DNA PCR. DNA extraction from isolated neuronal nuclei populations was performed via isopropanol precipitation. In brief, nuclei were incubated with proteinase K in 550 μl PK buffer (50 mM Tris pH 8.0, 0.1 M EDTA, 0.1 M NaCl, 1% SDS) overnight at 55 °C. Samples were then treated with RNase cocktail enzyme mix (ThermoFisher, Waltham, MA) for 2 h, followed by addition of 250 μl saturated NaCl. After centrifugation, supernatant was used for DNA precipitation by isopropanol and washed three times with 70% ethanol. DNAeasy and QIAamp DNA Mini kits (Qiagen, Valencia, CA) were also used according to the manufacturer's instructions. Purified DNA was stored at −20 °C for future use. High annealing stringency PCR was performed using either the FastStart PCR master mix (Sigma, St. Louis, MO) with PCR cycle settings: 95 °C 30 s, 65 °C for 30 s, and 72 °C 2.5 min for 40 cycles, or the Platinum SuperFi DNA polymerase (ThermoFisher, Waltham, MA) with cycle settings: 98 °C 10 s, 65 °C for APP and 52 °C for PSEN1 for 10 s, and 72 °C 1.5 min for APP and 1 min for PSEN1 for 40 cycles. Primer sequences are listed in Supplementary Table 1 . DNA in situ hybridization and RNA in situ hybridization. For DISH pretreatment, sorted nuclei were dried on Plus Gold slides (Fisher Scientific, Pittsburgh, PA). Nuclei were then treated with RNase cocktail enzyme mix (RNase A + RNase T1, 1:50) (ThermoFisher, Waltham, MA) at 40 °C for 60 min, followed by fixation in 1:10 dilution buffered formalin at room temperature for 5 min. After being washed with distilled water twice, slides were treated with hydrogen peroxide at room temperature for 10 min, target retrieval reagent at 95 °C for 15 min, followed by protease treatment at 40 °C for 10 min. Restriction enzyme was applied after protease treatment for 2 h as necessary in negative control experiments. DNA was then denatured (2×SSC, 70% formamide and 0.1% sodium dodecyl sulfate) at 80 °C for 20 min. After cooling the slides to room temperature, BaseScope probes were applied and incubated with nuclei at 40 °C overnight. Samples were then prepared for signal development. For RISH pretreatment, 10 μm fresh frozen human tissue sections was fixed in 1:10 dilution buffered formalin on ice for 10 min. After washing with PBS twice, tissue sections were placed in serial diluted ethanol 50%, 70% and 100%, 5 min for each step. Slides were then treated with hydrogen peroxide at room temperature for 10 min, followed by protease treatment at room temperature for 20 min. BaseScope probes were then incubated with tissue sections at 40 °C for 2 h. Hydrogen peroxide, 10× target retrieval buffer, proteases, custom BaseScope probes (Supplementary Table 1) , and BaseScope reagent kit-RED used for signal development were all purchased from Advanced Cell Diagnosis (ACD, Newark, CA). Duplex BaseScope reagent kit was also purchased from ACD. Nuclei and tissue sections were counterstained with haematoxylin. Zeiss AX10 Imager, M2 microscope and ZEN2 software were used for image acquisition. Images were thresholded, and foci number or size were quantified using ImageJ for statistical analysis. Agilent SureSelect hybridization enrichment and sequencing. The method is graphically represented in Extended Data Fig. 2i . Nuclei were isolated from human frontal cortex, labelled for NeuN, and NeuN-positive nuclei were isolated via FANS. Genomic DNA was extracted and fragmented into ~1.2 kb using sonication (Covaris, Woburn, MA). End repair reactions were performed and Illumina sequencing adaptors were ligated to genomic DNA. Library-prepped DNA was hybridized with custom Agilent SureSelect probes designed against the entire APP locus, including introns. Purified APP-containing genomic DNA sequences were then sequenced on an Illumina NextSeq (Illumina, San Diego, CA). Sequences were aligned to the human reference genome (GRCh38) using STAR (version 2.5.3a) with the settings: --outSAMattributes All --outFilterScoreMinOverLread 0.8 --outSJfilterCountTotalMin 1 1 1 1. Duplicate reads were marked and removed using Picard (version 2.1.1). Reads were then informatically analysed using IGV, the UCSC Genome Browser, and a custom imaging pipeline built in R. SMRT sequencing. Neuronal genomic DNA was isolated as described above and used for APP PCR and nested APP PCR. Platinum SuperFi DNA polymerase with 100× higher fidelity compared to native Taq (Invitrogen, Platinum SuperFi DNA Polymerase) was used under high annealing stringency (98 °C 10 s, 65 °C 10 s, and 72 °C 1.5 min, for 30 cycles). An aliquot of the first PCR product was used as a DNA template for nested PCR reactions. Multiple PCR reactions were pooled (149 reactions for Alzheimer's disease and 244 reactions for non-diseased) and purified by DNA Clean and Concentrator-5 (Zymo Research, Irvine, CA) for SMRT sequencing library preparation. PCR amplicons were repaired using SMRTbell template prep kit version 2.0 (PacBio) and purified using AMPure PB beads (PacBio, Menlo Park, CA). Adapters were ligated to DNA to create SMRTbell libraries. Sequencing polymerase was annealed and the SMRTbell library was loaded using Magbead binding. Raw bam sequencing files were converted to fastq format using the CCS algorithm in the SMRTLink software tool kit from PacBio. In CCS, reads were included in the fastq file only if 1) there were more than 20 passes of the sequencing polymerase over the DNA insert in the zero mode waveguide well and 2) the predicted accuracy in SMRTLink was calculated to be greater than 0.9999. These cutoffs generated ultra-high accuracy reads, the median Phred score of reads used was 93 [43] [44] [45] [46] , representing 99.999999% accuracy, with further quality filtering steps applied in our informatic analysis. This SMRT sequencing is comparable in fidelity to Sanger sequencing 43, 45 . Genomic data analyses with customized bioinformatic pipelines. Novel algorithms were developed to detect and analyse exon rearrangement in genes of interest. The algorithms were specifically designed to analyse long-read sequences generated by the Pacific Biosciences Sequel platform. A series of quality control (QC) procedures were performed before sequence processing to ensure high quality of the reads being analysed. Quality control: consensus sequence and read quality. PacBio circular consensus sequence (CCS) reads with fewer than 20 passes were filtered out to ensure overall sequence quality. Quality score distributions were examined: for APP gene PCR enriched sequences, average median read-wide Phred score was 93. In gencDNA analyses, we included only reads that met a mean Phred cutoff of >85. Quality control: sequencing artefacts. Owing to the intrinsic limits of PacBio SMRT sequencing technology, errors in homopolymers (that is, sequence ATTTG could be read as ATTTTG or ATTG in addition to ATTTG) are specially handled with a method that combines quality score information and reference sequence at the beginning of the homopolymer. The FASTQ files encoded uncertainty in the homopolymer run length in the first Phred score of each run. If this Phred score was lower than our threshold of 30, then this position was marked as a likely sequencing artefact and not a real variant. PCR primer filter. The reads were checked to ensure the correct start and end sites with forward and reverse PCR primer sequences. BLAST (command line tool 'blastn' 2.6.0+) was used to align primer sequences in either orientation to each read with word size 13, gap open penalty 0, and gap extension penalty 2. Any read in which both primers were not detected was filtered out. Furthermore, reads on the negative strand were reverse complemented in this step. BLAST seed length was optimized to avoid ambiguity and ensure sensitivity. Alignment to APP reference sequences. The Ensembl reference sequence for APP was downloaded from the GRCh38 reference human genome assembly using the UCSC Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) with RefSeq accession number NM_000484.3. Because the PCR primers begin at the start codon and end with the stop codon, sequences of exons 1 and 18 were trimmed to these positions so that only the coding sequence of each of the 18 exons was kept and stored as a FASTA file. Then, we used BLAST to look for local alignment between 18 exons and each quality-filtered CCS read; blastn parameters used: -outfmt 6, -wordsize 25, -gapopen 0, -gapextend 2. We used the resulting alignment coordinates to mark regions of each read covered by exons. This allowed us to analyse exon arrangements, lengths and patterns of exon-exon junctions. SNV and INDEL analysis. First, we used reference sequences of APP exons to replace low quality individual nucleotides (potential homopolymer runs and other errors) within each read with their reference APP exon counterpart. Then, we analysed BLAST local alignments between each exon (or part of an exon) and the read sequence, nucleotide by nucleotide, to look for alignment mismatches. If the mismatch position was a different nucleotide, we assigned it as a single nucleotide variant (SNV); if the mismatch position was a hyphen in the exon sequence, we assigned it as an insertion and if the mismatch position was a hyphen in the read sequence we assigned it as a deletion. gencDNA production in culture. The method is graphically represented in Fig. 4a . CHO cells were serum-deprived for 2 days, followed by addition of reverse transcriptase inhibitors AZT (100 μM) and ABC (10 μM) (Tocris, Minneapolis, MN) until the end of the experiment. The medium was changed daily with fresh reverse transcriptase inhibitors. Cells were transfected with APP-751 driven by the CAG promoter by GenJet (SignaGen Laboratories, Gaithersburg, MD) on day 3, then on day 4, cells were treated with 0 μM, 5 μM, or 50 μM hydrogen peroxide (Fisher Scientific) for 2 h. After 1 day, cells were collected and genomic DNA was extracted for PCR analysis. In vitro reverse transcriptase activity assay. Lysates were prepared in reverse transcriptase disruption buffer 47 , and contained cOmplete, EDTA-free protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and PhosSTOP phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). The assay was performed essentially as described 48 , except the assay was separated into two parts. One microgram of extract was used in the reverse transcription step of the assay. In addition, Primer A was used in the reverse transcription reaction cocktail instead of Primer B (Supplementary Information1). Reverse transcription was carried out at 37 °C for 45 min, followed by 15 min at 70 °C.
The reverse transcriptase product of this first step was assayed in triplicate by quantitative PCR. Levels of reverse transcription activity were determined by the Delta Cq method, compared to the activity in negative controls (water and no nucleotides), which were given Cq scores of 40. 100,000 picounits of SuperScript II Reverse Transcriptase (ThermoFisher Scientific) were used as a positive control for the assay.
Lysates for heat inactivation experiments were incubated for 15 min at 70 °C before the reverse transcription step. For inhibitor experiments, lysates were incubated with inhibitor in the presence of all the components of the reaction except for dNTPs. After 10 min at room temperature, dNTPs were added and the reaction was incubated at 37 °C as above. AZT-TP was purchased from TriLink Biotechnologies (San Diego, CA). Construction and retroviral transduction of synthetic human APP sequence targets. Phosphorylated oligonucleotides (Integrated DNA Technologies) composed of human APP target sequences with BamHI and BglII restriction sites on the 5′ ends were annealed and ligated into the BamHI site of the retroviral expression vector S-003-AB LZRSpBMN-linker-IRES-EGFP. All primer sequences for construction are listed in Supplementary Table 1. Single and concatamerized oligonucleotide inserts were identified by PCR using primers flanking the BamHI insertion site, and identified clones were sequenced to confirm insert copy number (Genewiz, La Jolla, CA). Helper-free ecotropic virus was produced by transfecting DNA constructs (Lipofectamine 2000, Thermo Fisher Scientific) with single or multiple copies of the oligonucleotide inserts into the retrovirus packaging line Phoenix-ECO. Forty-eight hours after transfection, retroviral supernatants were harvested, and 2 ml of selected virus was used for transduction of NIH-3T3 cells in 6-well plates. Retroviral transduction was carried out by removing the cell growth medium, replacing it with 2 ml retroviral supernatant containing 4 μg/ml polybrene, and spinning at 25 °C for 1 h at 2,800 r.p.m. Forty-eight hours after transduction, the percentage of GFP + cells, as identified by flow cytometry, was used to evaluate transduction efficiency. Cell culture. NIH-3T3 (DMEM, 5% FBS), CHO-K1 (RPMI, 10% FBS), SH-SY5Y (DMEM/F12, 10% FBS), IMR-90 (DMEM, 10% FBS) and HEK-293 (DMEM, 10% FBS) cells were purchased from ATCC and maintained at 37 °C under 5% CO 2 . Although HEK-293 is in the database of commonly misidentified cell lines, this cell line was used to show protein expression of our targets in mammalian cells and as gencDNA negative controls. For the indicated purpose, there is no concern regarding this cell line in the manuscript. Cells from ATCC and all reagents used were verified to be mycoplasma free. Western blot. Cells were harvested in RIPA buffer (100 mM Tris-HCl, pH 7.6, 250 mM NaCl, 0.1% sodium dodecyl sulfate, 0.2% deoxycholic acid, 0.5 mM dithiothreitol, 1 mM EDTA, 0.5% NP-40 and 1% Triton X-100), and proteins in each lysate were analysed using rat monoclonal anti-HA antibody (Clone 3F10, Roche) and horseradish peroxidase-conjugated goat anti-rat secondary antibody (Cell Signaling). Enhanced chemiluminescent substrate (Millipore) for the reaction was added, and the signal was detected by BioRad bioimaging system. Variant toxicity assay. SH-SY5Y cells were transfected with APP RNA variants by lipofectamine LTX (Life Technologies) overnight and further cultured under serum-deprived conditions for 7 days. Cell viability was determined by WST1 reagent (Roche Applied Science) according to the manufacturer's protocol. In brief, cells in 96-well plates were incubated with 100 μl WST1 reagent and culture medium in a ratio of 1:10 (v/v) per well at 37 °C for 2 h. The absorbance at 440 nm of samples normalized by a background control was measured by microplate ELISA reader. Statistics and reproducibility. All statistical analyses were completed using Prism Version 7 (GraphPad). Specific tests, number of data points (n), and P values are reported in Figures, figure legends 
Data availability
Fastq files of SMRT sequences performed on a PacBio Sequel and Illumina sequences on NextSeq500 have been deposited in NCBI Sequence Read Archive (BioProject ID: PRJNA493258). The PacBio produced RNA-seq data sets from whole brain and temporal lobe supporting the findings of this study are available at https://www.pacb.com/blog/data-release-alzheimer-brain-isoform-sequencingiso-seq-dataset, and from the authors upon reasonable request and with permission of PacBio, respectively. The source codes of the customized algorithms are available on GitHub (https://github.com/christine-liu/exonjunction and https://github.com/ taolonglab/varccs). Fig. 5j (non-parametric Kruskal-Wallis with Dunn's multiple comparisons test). **P < 0.01, ***P < 0.001, ****P < 0.0001. NS, not significant. d-f, Synthetic DNA targets containing the exon 16/17 junction sequence were introduced by retroviral transduction into NIH-3T3 cells, and the target sequence (provirus) identified by DISH 16/17 . A concatamer (×2) showed increased focus size, represented as a cumulative frequency distribution plot (e) and a box and whisker plot (f). Line, median; box, 75th-25th percentiles; whiskers, 90th-10th percentiles. Statistical significance was calculated using non-parametric Kruskal-Wallis test with Dunn's correction for multiple comparisons. ****P < 0.0001. 
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Extended data table 4 | dISh and RISh experiments and validation list
In, intron; Ex, exon; Exp, experimental; Neg, negative control; Pos, positive control; ED, Extended Data. DNA and RNA in situ hybridization experiments, positive and negative controls are summarized.
